Faculty profile

Girish Kulkarni

ResearcherToronto General Research InstituteUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Girish Kulkarni

Researcher

Toronto General Research Institute

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
20 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2020.
Supervised 3 trainees who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

201

Citations

h-index

165

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Bladder Cancer Cost-Effectiveness Policy Population Data Technology Therapy Access To Health Care Cost

Latest papers

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
The Journal of urology · 2026
Analysis of upper tract urothelial carcinoma in the Asian population.
BJU international · 2026
Automated vs. manual segmentation for small renal mass imaging.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026

All 60 publications

Latest funding

Bayesian analysis of the European Randomized Study of Screening for Prostate Cancer Rotter
CIHR · 2024 · Supervisor
$2,000
Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer
CIHR · 2023 · Co-investigator
$462,824
Development, validation, and evaluation of an organized prostate cancer screening policy leveraging a population-based machine learning model predicting clinically significant prostate cancer
CIHR · 2023 · Supervisor
$105,000

All 10 grants and awards

60 publications.

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

Joyce DD, Sharma V, Ratcliff GE, Barocas DA, Chang SS, Penson DF, Packiam VT, Kulkarni G, Wymer KM, Boorjian SA

The Journal of urology2026

DOI: 10.1097/ju.0000000000005126 PMID: 42150056

Analysis of upper tract urothelial carcinoma in the Asian population.

Qin S, Lim K, Tempo J, Ischia J, Bolton D, Fleshner N, Herrera-Cáceres JO, Klaassen Z, Goldberg H, Chandrasekar T, Alhunaidi O, Tan GH, Nason G, Ajib K, Kulkarni G, Woon D

BJU international2026

DOI: 10.1111/bju.70038 PMID: 41324171

Automated vs. manual segmentation for small renal mass imaging.

McAlpine K, Mirajkar N, Deniffel D, Kohan A, Krishna S, Kulkarni G, Seto E, Finelli A, Haider MA

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2026

DOI: 10.5489/cuaj.9476 PMID: 41701890

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Titus RS, Riveros C, Velasquez EL, Nguyen DD, Somawardana S, Singh A, Kaushik D, Sonpavde G, Zlotta A, Kulkarni G, Sridhar SS, Wallis CJD, Satkunasivam R

BJUI compass2026

DOI: 10.1002/bco2.70194 PMID: 42022227

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Pace KJC, Kwong JCC, Randhawa H, Ringa M, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Haile S, Ali A, Wettstein M, Chan A, Perlis N, Lee J, Hamilton R, Fleshner N, Finelli A, Jamal M, Papanikolaou F, Short T, Feifer A, Kulkarni G, Zlotta AR

BJU international2026

DOI: 10.1111/bju.70085 PMID: 41260885

Letter: Urology Publication Output in Potentially Predatory Journals From 2019 to 2024

Ahmad I, Cheruvathur JS, Al-Hasani H, Li T, Yadav P, Nguyen TT, Lee JY, Kulkarni G, Satkunasivam R, Lalani A-K

Investigative Urology2026

DOI: 10.1097/ju.0000000000005143

5-α Reductase Inhibitors and Prostate Cancer Mortality.

Hamilton RJ, Chavarriaga J, Khurram N, Lau C, Luo J, Liu N, Komisarenko M, Kulkarni G, Wallis C, Juurlink DN, Fleshner N, Finelli A

JAMA network open2024

DOI: 10.1001/jamanetworkopen.2024.30223 PMID: 39190306

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A

European journal of cancer (Oxford, England : 1990)2024

DOI: 10.1016/j.ejca.2024.113530 PMID: 38295556

Tranexamic Acid During Radical Cystectomy

Breau RH, Lavallée LT, Cagiannos I, Momoli F, Bryson GL, Kanji S, Morash C, Turgeon AF, Zarychanski R, Houston BL

JAMA Surgery202420 citations

DOI: 10.1001/jamasurg.2024.4183

Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.

Navarro-Domenech I, Arulanantham S, Liu ZA, Tjong M, Kong V, Malkov V, Tadic T, Fleshner N, Kulkarni G, Zlotta AR, Catton C, Berlin A, Sridhar S, Jiang DM, Chung P, Raman S

Radiation oncology (London, England)2023

DOI: 10.1186/s13014-023-02338-w PMID: 37730609

Something wrong or missing on this profile? Suggest a correction

Girish Kulkarni

Research

Latest papers

Latest funding

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Gu&#xe9;rin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

Analysis of upper tract urothelial carcinoma in the Asian population.

Automated vs. manual segmentation for small renal mass imaging.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-na&#xef;ve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Letter: Urology Publication Output in Potentially Predatory Journals From 2019 to 2024

5-&#x3b1; Reductase Inhibitors and Prostate Cancer Mortality.

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

Tranexamic Acid During Radical Cystectomy

Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.

Frequent collaborators

Antonio Finelli

Neil Fleshner

Alexandre Zlotta

Robert Hamilton

Nathan Perlis

Wassim Kassouf

Bobby Shayegan

Libni Eapen

Alan So

Sender Herschorn

Alejandro Berlin

Shabbir Alibhai

Peter Black

Dean Fergusson

Tony Lam

Mary Gospodarowicz

Aly-Khan Lalani

Dean Fergusson

Jordan Feld

Alice Wei

David Urbach

Karen Madsen

Philip Devereaux

Mohit Bhandari

Sameer Parpia

Joanna Dionne

John F Valliant

Himu Lukka

Cagla Eskicioglu

Bradley Allan Petrisor

Timothy Whelan

Edward Passos

John Agzarian

Paul Engels

Ilun Yang

Dennis Hong

Mark Norman Levine

Wojtek Wiercioch

Murray Krahn

Marko Simunovic

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

5-α Reductase Inhibitors and Prostate Cancer Mortality.